Glioblastoma: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• MGMT 20
• EGFR 14
• IDH 10
• STAT3 3
• TP53 0
• AKT 0
• mTOR 1
• PI3K 1
• PD-1 7
• ERK 0
• PD-L1 5
• STING 0
• YAP 0
• B7-H3 7
• MAPK 0
• PARP 1
• CTNNB1 0
• PTEN 1
• VEGF 5
• AMPK 0
• BRAF 1
• TERT 3
• FGFR 1
• PRMT5 5
• CDK4/6 0
• HDAC 0
• HIF-1 1
• IL-6 0
• NRF2 0
• PSMA 4
• MYC 2
• COX-2 0
• CXCR4 0
• EZH2 0
• CD47 0
• HER2 2
• JAK 0
• MEK 0
• MET 1
• METTL3 0
• TLR4 0
• ATM 2
• GPX4 0
• MDM2 0
• BCL-2 0
• CDKN2A 0
• CTLA-4 0
• FAK 0
• HSP90 0
• JNK 0
• MMP-9 1
• TNF 0
• CD19 0
• NF1 1
• NTRK 1
• TREM2 0
• AR 0
• CD40 1
• HMGB1 0
• IDO1 0

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 24+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Verteporfin for the Treatment of Recurrent High Grade EGFR-Mutated Glioblastoma

  NCT04590664· Emory University· Updated 28 Oct 2026

  “PI Decision”Registry text, quoted unchanged. Source

• Terminated

  A Study of TAS2940 in Participants With Locally Advanced or Metastatic Solid Tumor Cancer

  NCT04982926· Taiho Oncology, Inc.· Updated 14 Oct 2025

  “After careful review of Taiho's ongoing portfolio and data obtained so far in the context of broader landscape of clinical development in NSCLC HER2mut, Sponsor has made a strategic decision to terminate this study and not based on safety concerns.”Registry text, quoted unchanged. Source

• Withdrawn

  A Phase II, Open Label Study of ONC201 in Adults With EGFR-low Glioblastoma

  NCT04629209· Masonic Cancer Center, University of Minnesota· Updated 24 Nov 2023

  “Change in approach to study.”Registry text, quoted unchanged. Source

• Withdrawn

  The Addition of Chloroquine to Chemoradiation for Glioblastoma,

  NCT02432417· Maastricht Radiation Oncology· Updated 18 Nov 2023

  “The study was withdrawn due to a lack of funding. The researchers were unable to secure the necessary financial support to continue and complete the trial.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Surgical Window Study of CM93 in Subjects With Recurrent Glioblastoma (rGBM)

  NCT07927491· NYU Langone Health· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 93
• Organoids 33
• Mendelian Randomization Analysis 14
• CRISPR-Cas Systems 11
• Gene Expression Profiling 150
• Sequence Analysis, RNA 10
• Exome Sequencing 2
• Proteomics 47
• Metabolomics 21
• Mass Spectrometry 9
• Flow Cytometry 16
• Immunohistochemistry 22
• Liquid Biopsy 10
• Circulating Tumor DNA 3
• Xenograft Model Antitumor Assays 226
• Positron-Emission Tomography 37
• Magnetic Resonance Imaging 234
• Machine Learning 266
• Deep Learning 43
• Cohort Studies 54
• Genome-Wide Association Study 13

• spOT-NMF: gene expression deconvolution via optimal transport with proximity-aware niche mapping for spatial transcriptomics.

  Brief Bioinform, Nov 2026

• CCCView: A Knowledge Platform for Integrated Analysis of Spatial Transcriptomic Cell-Cell Communication.

  Int J Mol Sci, Oct 2026

• Exploring the Phytochemical Composition of Bitter Melon Fruit and Molecular Responses to Its Extract in U87 MG Glioblastoma Cells.

  Molecules, Oct 2026

• GlycoRNA-related cellular program scoring identifies Siglec- and myeloid-associated tumor microenvironments for glycoRNA validation.

  Front Immunol, Oct 2026

• A standardized patient-derived glioblastoma organoid platform for evaluating radiotherapy efficacy and overcoming resistance.

  Cell Rep Med, Oct 2026

• Reduced Gene Module for Spatial Transcriptomics Recapitulates Single-Cell Molecular Classifications of Glioblastoma.

  Pathol Int, Oct 2026

• Integrated Transcriptomic and Functional Analyses Identify SERPINE1 as a Ferroptosis-Associated Mediator of Glioblastoma Radioresistance.

  Front Biosci (Landmark Ed), Sept 2026

• Multistage Genetic, Transcriptomic, and Single-Cell Evidence Prioritizes MAP1LC3A among Ferroptosis-Related Genes in Glioblastoma.

  J Vis Exp, Sept 2026

• Whole-Transcriptome Profiling of Murine GL261 Glioma Reveals Signatures Consistent with Distinct Immune Reprogramming Induced by Oncolytic Virotherapy with VV-GMCSF-Lact and Anti-PD-1 Therapy.

  Int J Mol Sci, Sept 2026

• Conserved miRNA regulators of PD-1/PD-L1 in glioblastoma and colorectal cancer.

  RNA Biol, Sept 2026

See which targets of this disease your abstract mentions, and go to the people working on them.